MCID: SRC027
MIFTS: 44

Sarcoma, Synovial malady

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Sarcoma, Synovial

Aliases & Descriptions for Sarcoma, Synovial:

Name: Sarcoma, Synovial 54 13 13 42
Synovial Sarcoma 12 50 56 29 14 69
Synovialosarcoma 56
Sarcoma Synovial 52

Characteristics:

Orphanet epidemiological data:

56
synovial sarcoma
Inheritance: Not applicable; Age of onset: All ages;

HPO:

32
sarcoma, synovial:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 300813
Disease Ontology 12 DOID:5485
MeSH 42 D013584
NCIt 47 C3400
SNOMED-CT 64 302851001 63211008
Orphanet 56 ORPHA3273
UMLS via Orphanet 70 C0039101
ICD10 via Orphanet 34 C49.9
UMLS 69 C0039101

Summaries for Sarcoma, Synovial

NIH Rare Diseases : 50 synovial sarcoma is a rare and aggressive soft tissue sarcoma. in the early stages of the condition, it may cause no noticeable signs or symptoms. however, as the tumor grows larger, affected people may notice a lump or swelling. in some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. cells in these tumors are usually characterized by the presence of a translocation involving chromosomes x and 18. this translocation is specific to synovial sarcoma and is often used to diagnose the condition. treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy. last updated: 9/10/2015

MalaCards based summary : Sarcoma, Synovial, also known as synovial sarcoma, is related to epithelioid cell synovial sarcoma and spindle cell synovial sarcoma, and has symptoms including synovial sarcoma An important gene associated with Sarcoma, Synovial is SSX1 (SSX Family Member 1), and among its related pathways/superpathways are Glioma and Ras signaling pathway. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Related phenotypes are Increased shRNA abundance (Z-score > 2) and digestive/alimentary

Disease Ontology : 12 A synovium cancer which develops in the synovial membrane of the joints.

OMIM : 54 Synovial sarcomas, which represent approximately 10% of all soft tissue sarcomas, are aggressive spindle cell sarcomas... (300813) more...

Wikipedia : 71 A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily... more...

Related Diseases for Sarcoma, Synovial

Diseases related to Sarcoma, Synovial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 epithelioid cell synovial sarcoma 11.1
2 spindle cell synovial sarcoma 10.9
3 mediastinum synovial sarcoma 10.9
4 sarcoma 10.4
5 malignant epithelial mesothelioma 10.3 CDH1 KIT MUC1
6 clear cell ependymoma 10.3 MUC1 SSX1 VIM
7 marfanoid hypermobility syndrome 10.3 KIT MUC1 VIM
8 substance abuse 10.3 CDH1 CTNNB1 MUC1
9 sebaceous adenoma 10.3 KIT MUC1 VIM
10 adult myxoid chondrosarcoma 10.3 CTNNB1 KRT7
11 cerebral arterial disease 10.3 CTNNB1 KIT MDM2
12 mesenchymoma 10.3 KIT MUC1 VIM
13 cyanide-induced parkinsonism 10.3 CALB2 CDH1
14 papillary ependymoma 10.3 SSX1 SSX2B
15 differentiating neuroblastoma 10.3 CDH1 MUC1 VIM
16 aneurysm of sinus of valsalva 10.3 MDM2 MUC1 VIM
17 fitz-hugh-curtis syndrome 10.3 CTNNB1 KIT VIM
18 mediastinum liposarcoma 10.3 MDM2 MUC1 VIM
19 pilar sheath acanthoma 10.3 HMGA2 KIT VIM
20 coronary stenosis 10.3 MDM2 MUC1 VIM
21 gastrointestinal system cancer 10.3 CDH1 MUC1 VIM
22 invasive mole 10.3 KIT MUC1
23 temporal lobe neoplasm 10.3 CTNNB1 HMGA2 IGF1R
24 lung benign neoplasm 10.3 IGF1R MUC1 VIM
25 papillary serous adenocarcinoma 10.3 SS18 SSX2B
26 vulvar angiokeratoma 10.3 KRT7 MUC1 VIM
27 scirrhous adenocarcinoma 10.3 CDH1 MUC1 VIM
28 petrous apex meningioma 10.3 CALB2 MUC1 VIM
29 ovarian insufficiency due to fsh resistance 10.3 MET MUC1 VIM
30 appendix mucinous cystadenocarcinoma 10.3 KRT7 MUC1 VIM
31 lymphangiosarcoma 10.3 CALB2 MUC1 VIM
32 house allergic alveolitis 10.3 HMGA2 MDM2 MET
33 human granulocytic anaplasmosis 10.3 KIT MUC1 VIM
34 tanycytic ependymoma 10.3 CDH1 MUC1 SSX1 VIM
35 gestational trophoblastic neoplasm 10.3 CALB2 MUC1 VIM
36 chondroblastoma 10.3 CALB2 MUC1 VIM
37 popliteal pterygium syndrome, bartsocas-papas type 10.3 CTNNB1 KIT MUC1 VIM
38 carbon monoxide-induced parkinsonism 10.3 CALB2 KIT
39 hormone producing pituitary cancer 10.3 CALB2 KIT MDM2
40 handigodu disease 10.3 CALB2 VIM
41 nodular cutaneous amyloidosis 10.3 CDH1 CTNNB1 KRT7
42 enchondromatosis dwarfism deafness 10.3 CTNNB1 KIT MDM2 VIM
43 trophoblastic neoplasm 10.3 CALB2 KRT7 MUC1
44 thymic dysplasia 10.3 CALB2 MUC1
45 pleural lipoma 10.3 CALB2 HMGA2 MDM2
46 diarrhea, chronic, with villous atrophy 10.3 KIT MDM2 MUC1 VIM
47 unknown leukodystrophy 10.3 KRT19 VIM
48 paroxysmal nocturnal hemoglobinuria 10.3 CDH1 CTNNB1 MUC1
49 intestinal benign neoplasm 10.3 KRT7 MUC1 VIM
50 thymoma 10.3 CALB2 KRT7 MUC1

Graphical network of the top 20 diseases related to Sarcoma, Synovial:



Diseases related to Sarcoma, Synovial

Symptoms & Phenotypes for Sarcoma, Synovial

Clinical features from OMIM:

300813

Human phenotypes related to Sarcoma, Synovial:

32
id Description HPO Frequency HPO Source Accession
1 synovial sarcoma 32 HP:0012570

GenomeRNAi Phenotypes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 SSX2 SSX2B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.29 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 CTNNB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.29 IGF1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 SSX1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.29 IGF1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.29 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.29 SSX1 SSX2 SSX2B SSX3 SSX4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.29 IGF1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.29 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.29 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 VIM IGF1R CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.29 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.29 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.29 IGF1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 SSX2B SSX3 SSX4 IGF1R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.29 SSX1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.29 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.29 KIT SSX2 SSX2B VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 IGF1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.29 SSX2B SSX3 CTNNB1 IGF1R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 SSX4 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.29 SSX4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.29 SSX1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 SSX1 VIM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 SSX4 CTNNB1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 CTNNB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.29 CTNNB1 IGF1R
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.29 SSX2 SSX2B SSX3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.29 SSX3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.29 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.29 SSX2 SSX2B
39 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.29 SSX4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 VIM KIT IGF1R
41 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.29 KIT
42 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.29 SSX3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.29 KIT
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.25 SSX2
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.25 MET
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.25 MET
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.25 SSX4
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.25 MET
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.25 SSX2B SSX3 SSX4 VIM
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.25 MET
51 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.25 CTNNB1
52 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.25 SSX2 SSX2B CTNNB1 MET
53 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 10.25 VIM
54 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 10.25 MET
55 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.25 SSX4
56 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.25 SSX2 SSX2B
57 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.25 VIM
58 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 10.25 MET
59 Decreased cell migration GR00055-A-1 9.65 CTNNB1 IGF1R MET MUC1 VIM
60 Decreased substrate adherent cell growth GR00193-A-1 9.56 IGF1R KIT MET
61 Decreased substrate adherent cell growth GR00193-A-2 9.56 KIT
62 Decreased substrate adherent cell growth GR00193-A-3 9.56 MET
63 Decreased substrate adherent cell growth GR00193-A-4 9.56 IGF1R KIT MET

MGI Mouse Phenotypes related to Sarcoma, Synovial:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 CDH1 CTNNB1 ELF3 IGF1R KIT KRT19
2 embryo MP:0005380 9.61 CDH1 CTNNB1 IGF1R KIT KRT19 MDM2
3 neoplasm MP:0002006 9.17 CDH1 CTNNB1 IGF1R KIT KRT19 MDM2

Drugs & Therapeutics for Sarcoma, Synovial

Drugs for Sarcoma, Synovial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
14
Idarubicin Approved Phase 3 58957-92-9 42890
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
23 Isophosphamide mustard Phase 3,Phase 2,Phase 1
24 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Anti-Infective Agents Phase 3,Phase 1,Phase 2
28 Antimitotic Agents Phase 3,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
31 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2
35 Trofosfamide Phase 3
36 Anti-Allergic Agents Phase 3
37 Antipruritics Phase 3
38 Dermatologic Agents Phase 3
39 Gastrointestinal Agents Phase 3
40 Histamine Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Neurotransmitter Agents Phase 3
44
Serotonin Phase 3 50-67-9 5202
45 Serotonin Agents Phase 3
46 Serotonin Antagonists Phase 3
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
49
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
50
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 94)
id Name Status NCT ID Phase
1 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
3 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
4 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
6 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
12 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3
13 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
14 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Not yet recruiting NCT03016819 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
16 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
18 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
19 Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00052754 Phase 2
20 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00104949 Phase 2
21 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma Completed NCT01281865 Phase 1, Phase 2
22 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2
23 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
24 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2
25 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2
26 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
27 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
28 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2
29 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2
30 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
31 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
32 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
33 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Completed NCT00030667 Phase 2
34 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Completed NCT00297258 Phase 2
35 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2
36 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
37 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
38 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
39 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
40 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
41 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
42 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
43 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
44 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2
45 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
46 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
47 DHEA in Synovial Sarcoma Patients Recruiting NCT02683148 Phase 1, Phase 2
48 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases Recruiting NCT02181829 Phase 2
49 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Recruiting NCT01343043 Phase 1, Phase 2
50 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2

Search NIH Clinical Center for Sarcoma, Synovial

Cochrane evidence based reviews: sarcoma, synovial

Genetic Tests for Sarcoma, Synovial

Genetic tests related to Sarcoma, Synovial:

id Genetic test Affiliating Genes
1 Synovial Sarcoma 29

Anatomical Context for Sarcoma, Synovial

Publications for Sarcoma, Synovial

Variations for Sarcoma, Synovial

Cosmic variations for Sarcoma, Synovial:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM480 HRAS soft tissue,lower leg,synovial sarcoma,NS c.34G>A p.G12S 7
2 COSM1745010 MYOD1 soft tissue,upper leg,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 4
3 COSM33732 IDH2 soft tissue,upper leg,haemangioma,spindle cell c.515G>T p.R172M 4

Copy number variations for Sarcoma, Synovial from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 120197 18 21850214 21924609 Translate SS18 Synovial sarcoma

Expression for Sarcoma, Synovial

Search GEO for disease gene expression data for Sarcoma, Synovial.

Pathways for Sarcoma, Synovial

Pathways related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 CDH1 CTNNB1 IGF1R KIT MDM2 MET
2
Show member pathways
12.52 CDH1 CTNNB1 IGF1R KIT MET
3 12.33 CDH1 CTNNB1 IGF1R KIT MDM2 MET
4
Show member pathways
12.27 CTNNB1 IGF1R MDM2 MET
5 12.25 CDH1 KRT19 KRT7 MUC1 VIM
6 12.24 IGF1R KIT MDM2 MET
7 12.07 CTNNB1 IGF1R MDM2 MET
8
Show member pathways
12.07 CDH1 CTNNB1 IGF1R KIT MDM2
9
Show member pathways
11.68 CDH1 CTNNB1 MET
10 11.55 CDH1 CTNNB1 MET
11 11.48 HMGA2 IGF1R MDM2 MET SS18 SSX1
12 11.31 CDH1 CTNNB1 IGF1R MET
13 11.18 CDH1 CTNNB1 MET
14 10.86 CDH1 CTNNB1 IGF1R MET
15 10.62 CDH1 CTNNB1

GO Terms for Sarcoma, Synovial

Cellular components related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical junction complex GO:0043296 9.16 CDH1 CTNNB1
2 catenin complex GO:0016342 8.96 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.72 CTNNB1 HMGA2 IGF1R KIT MDM2
2 positive regulation of gene expression GO:0010628 9.65 CTNNB1 HMGA2 KIT MDM2 VIM
3 cellular response to indole-3-methanol GO:0071681 9.16 CDH1 CTNNB1
4 entry of bacterium into host cell GO:0035635 9.13 CDH1 CTNNB1 MET
5 negative regulation of nucleic acid-templated transcription GO:1903507 9.02 SSX1 SSX2 SSX2B SSX3 SSX4
6 transcription, DNA-templated GO:0006351 10.02 CTNNB1 ELF3 HMGA2 SS18 SSX1 SSX2

Molecular functions related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CDH1 CTAG1B CTNNB1 ELF3 HMGA2 IGF1R
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 IGF1R KIT MET
3 transcription corepressor activity GO:0003714 9.02 SSX1 SSX2 SSX2B SSX3 SSX4

Sources for Sarcoma, Synovial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....